Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
7.06
+0.31 (4.59%)
At close: Aug 19, 2026, 4:00 PM EDT
7.18
+0.12 (1.70%)
After-hours: Aug 19, 2026, 6:54 PM EDT

Foghorn Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
36.7430.9122.634.1619.231.32
Revenue Growth
51.98%36.75%-33.83%77.63%1357.77%206.74%
Cost of Revenue
78.8385.4794.53109.69105.6280.33
Gross Profit
-42.09-54.56-71.93-75.53-86.39-79.01
Selling, General & Admin
26.3827.5528.3632.3730.7521.73
Operating Expenses
26.3827.5528.3632.3730.7521.73
Operating Income
-68.48-82.11-100.29-107.91-117.14-100.73
Interest Expense
------1.91
Interest & Investment Income
7.18.7511.910.885.680.06
Other Non Operating Income (Expenses)
1.083.364.162.832.582.49
EBT Excluding Unusual Items
-60.3-70-84.22-94.2-108.88-100.09
Asset Writedown
-5.91-5.91-2.4---
Other Unusual Items
1.631.63----1.23
Pretax Income
-64.58-74.28-86.62-94.2-108.88-101.32
Income Tax Expense
---4.23--
Net Income
-64.58-74.28-86.62-98.43-108.88-101.32
Net Income to Common
-64.58-74.28-86.62-98.43-108.88-101.32
Net Income Growth
------
Shares Outstanding (Basic)
676355424237
Shares Outstanding (Diluted)
676355424237
Shares Change
5.91%14.72%30.79%0.92%11.89%236.49%
EPS (Basic)
-0.97-1.18-1.58-2.34-2.62-2.73
EPS (Diluted)
-0.97-1.18-1.58-2.34-2.62-2.73
EPS Growth
------
Free Cash Flow
-84.29-86.15-101.31-119.33192.4-53.56
Free Cash Flow Per Share
-1.27-1.37-1.84-2.844.63-1.44
Gross Margin
-114.57%-176.51%--221.15%--
Operating Margin
-186.38%-265.64%-443.70%-315.93%-609.20%-7637.15%
Profit Margin
-175.78%-240.33%-383.24%-288.17%-566.27%-7681.58%
Free Cash Flow Margin
-229.43%-278.72%-448.24%-349.38%1000.63%-4060.88%
EBITDA
-66.35-78.78-97.17-104.46-113.82-97.51
EBITDA Margin
-180.61%-254.86%----
D&A For EBITDA
2.123.333.123.453.323.23
EBIT
-68.48-82.11-100.29-107.91-117.14-100.73
EBIT Margin
-186.38%-265.64%----
SEC Filings: 10-K · 10-Q